Differential CTLA-4 expression in human CD4+ versus CD8 + T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation

Genes and Immunity

Volumn 15, Issue 1, 2014, Pages 25-32

  Chan, D V ^a   Gibson, H M ^a,b   Aufiero, B M ^b   Wilson, A J ^b   Hafner, M S ^b   Mi, Q S ^b   Wong, H K ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b HENRY FORD HOSPITAL   (United States)

Author keywords

Acetylation; CD4 T cells; CTLA 4; NFAT

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MESSENGER RNA; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFAT1; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL STIMULATION; CONTROLLED STUDY; GENE ACTIVATION; GENE EXPRESSION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; NORMAL HUMAN; PRIORITY JOURNAL; PROMOTER REGION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; UPREGULATION;

MURINAE;

ACETYLATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; CTLA-4 ANTIGEN; GENE EXPRESSION REGULATION; HISTONES; HUMANS; LYMPHOCYTE ACTIVATION; NFATC TRANSCRIPTION FACTORS; PROMOTER REGIONS, GENETIC; T-LYMPHOCYTES, REGULATORY; UP-REGULATION;

EID: 84895864219     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2013.57     Document Type: Article

References (62)

1. Dariavach P, Matté i M-G, Golstein P, Lefranc M-P. Human Ig superfamily CTLA-4 gene: Chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains. Eur J Immunol 1988; 18: 1901-1905
2. Harper K, Balzano C, Rouvier E, Mattei M, Luciani M, Golstein P. CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J Immunol 1991; 147: 1037-1044
3. Auchincloss H, Turka LA. CTLA-4: Not all costimulation is stimulatory. J Immunol 2011; 187: 3457-3458
4. Lindsten T, Lee K, Harris E, Petryniak B, Craighead N, Reynolds P et al. Characterization of CTLA-4 structure and expression on human T cells. J Immunol 1993; 151: 3489-3499
5. Friedline RH, Brown DS, Nguyen H, Kornfeld H, Lee J, Zhang Y et al. CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J Exp Med 2009; 206: 421-434
6. Schmidt EM, Wang CJ, Ryan GA, Clough LE, Qureshi OS, Goodall M et al. Ctla-4 controls regulatory T cell peripheral homeostasis and is required for suppression of pancreatic islet autoimmunity. J Immunol 2009; 182: 274-282
7. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008; 322: 271-275
8. Zheng SG, Wang JH, Stohl W, Kim KS, Gray JD, Horwitz DA. TGF-beta requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+CD25+ regulatory cells. J Immunol 2006; 176: 3321-3329
9. Chuang E, Fisher TS, Morgan RW, Robbins MD, Duerr JM, Vander Heiden MG et al. The CD28 and CTLA-4 receptors associate with the serine/threonine phosphatase PP2A. Immunity 2000; 13: 313-322
10. Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006; 18: 206-213
11. Wolchok JD, Saenger Y. The Mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist 2008; 13: 2-9
12. Stamper CC, Zhang Y, Tobin JF, Erbe DV, Ikemizu S, Davis SJ et al. Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses. Nature 2001; 410: 608-611
13. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995; 3: 541-547
14. Tivol E, Boyd S, McKeon S, Borriello F, Nickerson P, Strom T et al. CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice. J Immunol 1997; 158: 5091-5094
15. Howard TD, Postma DS, Hawkins GA, Koppelman GH, Zheng SL, Wysong AK et al. Fine mapping of an IgE-controlling gene on chromosome 2q: Analysis of CTLA4 and CD28. J Allergy Clin Immunol 2002; 110: 743-751
16. Tomer Y, Greenberg DA, Barbesino G, Concepcion E, Davies TF. CTLA-4 and not CD28 is a susceptibility gene for thyroid autoantibody production. J Clin Endocrinol Metab 2001; 86: 1687-1693
17. Hizawa N, Yamaguchi E, Jinushi E, Konno S, Kawakami Y, Nishimura M. Increased total serum IgE levels in patients with asthma and promoter polymorphisms at CTLA4 and FCER1B. J Allergy Clin Immunol 2001; 108: 74-79
18. Marron MP, Raffel LJ, Garchon HJ, Jacob CO, Serrano-Rios M, Martinez Larrad MT et al. Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA4 polymorphisms in multiple ethnic groups. Hum Mol Genet 1997; 6: 1275-1282
19. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003; 423: 506-511
20. Nithiyananthan R, Heward JM, Allahabadia A, Franklyn JA, Gough SC. Polymorphism of the CTLA-4 gene is associated with autoimmune hypothyroidism in the United Kingdom. Thyroid 2002; 12: 3-6
21. Kotsa K, Watson PF, Weetman AP. A CTLA-4 gene polymorphism is associated with both Graves disease and autoimmune hypothyroidism. Clin Endocrinol (Oxf) 1997; 46: 551-554
22. Wong HK, Wilson AJ, Gibson HM, Hafner MS, Hedgcock CJ, Berger CL et al. Increased expression of CTLA-4 in malignant T-cells from patients with mycosis fungoides-cutaneous T cell lymphoma. J Invest Dermatol 2006; 126: 212-219
23. Chong BF, Wilson AJ, Gibson HM, Hafner MS, Luo Y, Hedgcock CJ et al. Immune function abnormalities in peripheral blood mononuclear cell cytokine expression differentiates stages of cutaneous T-cell lymphoma/mycosis fungoides. Clin Cancer Res 2008; 14: 646-653
24. Freeman GJ, Lombard DB, Gimmi CD, Brod SA, Lee K, Laning JC et al. CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production. J Immunol 1992; 149: 3795-3801
25. Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N et al. Immunologic self-Tolerance maintained by Cd25+Cd4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-Associated antigen 4. J Exp Med 2000; 192: 303-310
26. Wu Y, Borde M, Heissmeyer V, Feuerer M, Lapan AD, Stroud JC et al. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 2006; 126: 375-387
27. Jain N, Nguyen H, Chambers C, Kang J. Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity. Proc Natl Acad Sci 2010; 107: 1524-1528
28. Gibson HM, Hedgcock CJ, Aufiero BM, Wilson AJ, Hafner MS, Tsokos GC et al. Induction of the CTLA-4 gene in human lymphocytes is dependent on NFAT binding the proximal promoter. J Immunol 2007; 179: 3831-3840
29. Alegre ML, Shiels H, Thompson CB, Gajewski TF. Expression and function of CTLA-4 in Th1 and Th2 cells. J Immunol 1998; 161: 3347-3356
30. Weyand CM, Goronzy J, Fathman CG. Modulation of CD4 by antigenic activation. J Immunol 1987; 138: 1351-1354
31. Morvan PY, Picot C, Dejour R, Genetet B, Genetet N. Distinct pattern of IL-2 and IFN-gamma gene expression in CD4 and CD8 T cells: Cytofluorometric analysis at a single cell level using non-radioactive probes. Cell Mol Biol (Noisy-le-grand) 1995; 41: 945-957
32. Cron RQ, Bort SJ, Wang Y, Brunvand MW, Lewis DB. T cell priming enhances IL-4 gene expression by increasing nuclear factor of activated T cells. J Immunol 1999; 162: 860-870
33. Zhou B, Cron RQ, Wu B, Genin A, Wang Z, Liu S et al. Regulation of the murine Nfatc1 gene by NFATc2. J Biol Chem 2002; 277: 10704-10711
34. Torgerson TR, Genin A, Chen C, Zhang M, Zhou B, Añover-Sombke S et al. FOXP3 inhibits activation-induced NFAT2 expression in T cells thereby limiting effector cytokine expression. J Immunol 2009; 183: 907-915
35. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995; 182: 459-465
36. Krummel MF, Allison JP. Pillars article: CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995; 182: 459-465
37. Perkins D, Wang Z, Donovan C, He H, Mark D, Guan G et al. Regulation of CTLA-4 expression during T cell activation. J Immunol 1996; 156: 4154-4159
38. Egen JG, Kuhns MS, Allison JP. CTLA-4: New insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002; 3: 611-618
39. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271: 1734-1736
40. Pandiyan P, Hegel JK, Krueger M, Quandt D, Brunner-Weinzierl MC. High IFNgamma production of individual CD8 T lymphocytes is controlled by CD152 (CTLA-4). J Immunol 2007; 178: 2132-2140
41. Fleissner D, Frede A, Knott M, Knuschke T, Geffers R, Hansen W et al. Generation and function of immunosuppressive human and murine CD8+ T cells by transforming growth factor-beta and retinoic acid. Immunology 2011; 134: 82-92
42. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996; 14: 233-258
43. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1: 405-413
44. Gattinoni L, Ranganathan A, Surman DR, Palmer DC, Antony PA, Theoret MR et al. CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent. Blood 2006; 108: 3818-3823
45. Pedicord VA, Montalvo W, Leiner IM, Allison JP. Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance. Proc Natl Acad Sci USA 2011; 108: 266-271
46. Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 1996; 183: 2533-2540
47. Williams MA, Tyznik AJ, Bevan MJ. Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature 2006; 441: 890-893
48. Ayukawa H, Matsubara T, Kaneko M, Hasegawa M, Ichiyama T, Furukawa S. Expression of CTLA-4 (CD152) in peripheral blood T cells of children with influenza virus infection including encephalopathy in comparison with respiratory syncytial virus infection. Clin Exp Immunol 2004; 137: 151-155
49. Jago CB, Yates J, Camara NO, Lechler RI, Lombardi G. Differential expression of CTLA-4 among T cell subsets. Clin Exp Immunol 2004; 136: 463-471
50. Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG et al. A new member of the immunoglobulin superfamily-CTLA-4. Nature 1987; 328: 267-270
51. Leung-Theung-Long S, Mondor I, Guiraud M, Lamare C, Nagaleekar V, Paulet PE et al. Impaired NFAT transcriptional activity in antigen-stimulated CD8 T cells linked to defective phosphorylation of NFAT transactivation domain. J Immunol 2009; 182: 6807-6814
52. Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007; 30: 825-830
53. Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 2010; 33: 828-833
54. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE et al. CTLA-4 blockade with ipilimumab: Long-Term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012; 18: 2039-2047
55. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723
56. Yuan J, Ginsberg B, Page D, Li Y, Rasalan T, Gallardo H et al. CTLA-4 blockade increases antigen-specific CD8+ T cells in prevaccinated patients with melanoma: Three cases. Cancer Immunol Immunother 2011; 60: 1137-1146
57. Weber JS, Hamid O, Chasalow SD, Wu DY, Parker SM, Galbraith S et al. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma. J Immunother 2012; 35: 89-97
58. Khattri R, Auger JA, Griffin MD, Sharpe AH, Bluestone JA. Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses. J Immunol 1999; 162: 5784-5791
59. Lindsten T, Lee KP, Harris ES, Petryniak B, Craighead N, Reynolds PJ et al. Characterization of CTLA-4 structure and expression on human T cells. J Immunol 1993; 151: 3489-3499
60. Freeman GJ, Lombard DB, Gimmi CD, Brod SA, Lee K, Laning JC et al. CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production. J Immunol 1992; 149: 3795-3801
61. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-Time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408
62. Weinmann AS, Bartley SM, Zhang T, Zhang MQ, Farnham PJ. Use of chromatin immunoprecipitation to clone novel E2F target promoters. Mol cell biol 2001; 21: 6820-6832.